Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.25 | ||
| Price to Tang. Book | 0.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.87% | ||
| Return on Equity | -68.21% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EoCene Ltd., formerly Galmed Pharmaceuticals Ltd., is an Israel-based healthcare technology and biopharmaceutical company engaged in the development of therapeutic products, medical devices, and healthcare technologies. The Company focuses on gastrointestinal diseases, gastrointestinal oncology, and related medical conditions through a portfolio of pharmaceutical and medical device programs. Its activities include research, development, clinical evaluation, and commercialization of therapeutic candidates and medical technologies. The Company’s portfolio includes Aramchol, a therapeutic candidate for liver and oncology-related indications, and medical device technologies developed through its subsidiary Colospan Ltd. for gastrointestinal and colorectal applications. EoCene Ltd. conducts its operations through biopharmaceutical, medical device, and healthcare technology activities.
Directors
- Allen Baharaff PRE (56)
- Yohai Stenzler CFO (38)
- Guy Nehemya COO (36)
- Liat Hayardeny CSO (54)
- David Sidransky LED (61)
- Marshall Heinberg DRC (63)
- Carol Brosgart IND (70)
- Shmuel Nir IND (59)
- Amir Poshinski IND (60)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 31st, 2013
- Public Since
- March 13th, 2014
- No. of Shareholders
- 8
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,041,565
- Address
- 16 Abba Hillel Silver Rd., RAMAT GAN, 5250608
- Web
- https://www.galmedpharma.com
- Phone
- +972 36938448
- Auditors
- Brightman Almagor Zohar & Co
Latest News for EOCN
Upcoming Events for EOCN
Q3 2026 Galmed Pharmaceuticals Ltd Earnings Release
Q4 2026 Galmed Pharmaceuticals Ltd Earnings Release
Similar to EOCN
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 20:30 UTC, shares in Eocene are trading at $3.03. This share price information is delayed by 15 minutes.
Shares in Eocene last closed at $3.03 and the price had moved by -72.25% over the past 365 days. In terms of relative price strength the Eocene share price has underperformed the S&P500 Index by -75.28% over the past year.
The overall consensus recommendation for Eocene is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEocene does not currently pay a dividend.
Eocene does not currently pay a dividend.
Eocene does not currently pay a dividend.
To buy shares in Eocene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.03, shares in Eocene had a market capitalisation of $3.16m.
Here are the trading details for Eocene:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EOCN
Based on an overall assessment of its quality, value and momentum Eocene is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Eocene is $12.00. That is 296.04% above the last closing price of $3.03.
Analysts covering Eocene currently have a consensus Earnings Per Share (EPS) forecast of -$11.41 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eocene. Over the past six months, its share price has underperformed the S&P500 Index by -43.15%.
As of the last closing price of $3.03, shares in Eocene were trading -35.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eocene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eocene's management team is headed by:
- Allen Baharaff - PRE
- Yohai Stenzler - CFO
- Guy Nehemya - COO
- Liat Hayardeny - CSO
- David Sidransky - LED
- Marshall Heinberg - DRC
- Carol Brosgart - IND
- Shmuel Nir - IND
- Amir Poshinski - IND